Toward better quality of anticancer generics in India

Abstract

Treatment of cancer is limited by affordability of patients in the many developing countries including India. Generic drug manufacturers have responded to this scenario by making drugs available at affordable costs, often at less than 10% the cost of the original brand. In our practice, it is found that there is a three-fold higher prescription of generic brands compared to innovator, accompanied by cost savings of up to 80% per prescription. Unfortunately, the regulatory environment prevailing in India is not geared to ensure satisfactory quality of generic products. The standards set by the regulatory agencies for establishing equivalence of generics vis-ΰ-vis the innovator product allow anticancer generics to enter markets without undergoing clinical evaluation. Many drug manufacturing units in India flout good manufacturing practice norms, which was evident during the center for drug evaluation and research classifications inspection in the year 2006. Inferior drugs have therefore, made their way into the Indian markets, compromising the quality of care. The system of drug manufacturing and marketing approval needs a major overhaul, including regular inspection of manufacturing facilities. Bioequivalence should be made mandatory for all oral formulations. Unless these measures are rigidly implemented, the benefits of generic substitution would be seriously undermined.

A comparison of asparaginase activity in generic formulations of E.coli derived L‐ asparaginase: In‐vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia

“…Additionally, there is no strict definition of comparability as there is for oral formulations. It is left up to the SLA in many cases to determine the quality control measures necessary to approve a drug in their state which has led to heterogeneous practices throughout India and possibly a lax regulatory environment …”

Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan

“…In this study, the overall affordability for both OBs and LPGs was found to be 55.5% which makes cancer a catastrophic disease for local masses [ 33 ]. Another dilemma of LMICs is that the local masses are unaware of the importance of health insurance [ 34 ]. But sometimes these insurance policies fail to provide benefits or demand substantial co-payment [ 35 ].…”

Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan

“…Another dilemma of LMICs is that the local masses are unaware of the importance of health insurance. 39 Insurance policies fail to provide benefits or demand substantial copayment. 40 Therefore, in 2014 the Pakistani government took an initiative in the form of the Prime Minister National Health Insurance Program.…”